G. Lamont

发表

Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators.

R. A. Norman, James S. Scott, A. Bailey, 2015, Journal of medicinal chemistry.

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.

Peter Ballard, Simon J Brown, Nathaniel G. Martin, 2014, Journal of medicinal chemistry.

Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors.

E. Hennessy, C. Chuaqui, A. Ferguson, 2016, ACS medicinal chemistry letters.

Synthesis of the Novel Tetrahydropyrazolo[3,4‐c]pyridin‐5‐one Scaffold.

G. Lamont, Kevin Blades, N. Howe, 2015 .

Synthesis of 3-(hetero)aryl tetrahydropyrazolo[3,4-c]pyridines by Suzuki-Miyaura cross-coupling methodology.

G. Lamont, Matthew R. Box, P. Kemmitt, 2014, The Journal of organic chemistry.

Expanding the scope of silane-mediated hydrodehalogenation reactions

G. Lamont, B. Hayter, Benjamin E. Partridge, 2013 .

Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRASG12C.

Doyle J Cassar, Nichola L. Davies, J. Breed, 2022, Journal of medicinal chemistry.

Optimized scale up of 3-pyrimidinylpyrazolo[1,5- a ]pyridine via Suzuki coupling; a general method of accessing a range of 3-(hetero)arylpyrazolo[1,5- a ]pyridines

G. Lamont, Paul A. Bethel, P. Kemmitt, 2012 .

Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.

Peter Ballard, Andrew G. Leach, Jason G Kettle, 2013, Journal of medicinal chemistry.

Chemical Biology Approaches Confirm MCT4 as the Therapeutic Target of a Cellular Optimized Hit.

G. Lamont, M. P. Castaldi, Andrew X. Zhang, 2023, ACS chemical biology.

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

M. O’Connor, S. Fawell, B. Davies, 2019, Nature Communications.

Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor.

G. Lamont, D. Buttar, S. Glossop, 2012, Bioorganic & medicinal chemistry letters.

The discovery of 7-methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor.

B. Davies, M. Vázquez‐Chantada, G. Lamont, 2019, Journal of medicinal chemistry.

Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology.

G. Lamont, D. Buttar, S. Critchlow, 2022, Journal of medicinal chemistry.

Identification and optimisation of 7-azaindole PAK1 inhibitors with improved potency and kinase selectivity

E. Hennessy, C. Chuaqui, A. Ferguson, 2014 .

Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK.

B. Davies, M. Vázquez‐Chantada, G. Lamont, 2022, ACS medicinal chemistry letters.

Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRASG12C with Demonstrable CNS Penetration.

Doyle J Cassar, Nichola L. Davies, J. Breed, 2023, Journal of medicinal chemistry.